|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,005 DKK | +0.24% |
|
+1.93% | +44.25% |
| 12:42pm | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
| 09:22am | NOVO NORDISK : UBS gives a Neutral rating | ZD |
SHANGHAI, June 25 (Reuters) - Novo Nordisk's drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday. (Reporting by Andrew Silver; Editing by Jacqueline Wong)
| 1st Jan change | Capi. | |
|---|---|---|
| +44.25% | 638B | |
| +56.70% | 819B | |
| -6.69% | 351B | |
| +19.32% | 329B | |
| +9.65% | 298B | |
| +16.89% | 242B | |
| +2.21% | 225B | |
| +13.35% | 217B | |
| +9.59% | 168B | |
| -2.71% | 158B |
NOVO NORDISK A/S 
